PVRIG and cancer: Up to now there is only one anti-PVRIG antibody used in a clinical trial for cancer immunotherapy, COM701, that is being tested in a phase 1 clinical trial (NCT03667716) to evaluate its safety, tolerability and preliminary clinical activity, as monotherapy or in combination with Nivolumab, in patients with advanced solid tumors including non-small cell lung cancer, ovarian, breast and endometrial cancer.